# Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively

> **NCT01868243** · PHASE2,PHASE3 · TERMINATED · sponsor: **Hospital Ana Nery** · enrollment: 27 (actual)

## Conditions studied

- Primary Disease

## Interventions

- **DRUG:** Dabigatran
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT01868243
- **Lead sponsor:** Hospital Ana Nery
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-08
- **Primary completion:** 2014-09
- **Final completion:** 2014-10
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** because a significant decrease of viable candidates for the study.
- **Last updated:** 2015-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01868243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01868243, "Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01868243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*